查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947944

补体C5重组单株抗体市场按应用、产品类型、最终用户和研究领域划分－全球预测，2026-2032年

Complement C5 Recombinant Monoclonal Antibody Market by Application, Product Type, End User, Research Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年补体 C5 重组单株抗体市值为 88.6 亿美元，预计到 2026 年将成长至 93.7 亿美元，到 2032 年将达到 148.1 亿美元，复合年增长率为 7.61%。

关键市场统计数据
基准年 2025 88.6亿美元
预计年份：2026年 93.7亿美元
预测年份 2032 148.1亿美元
复合年增长率 (%) 7.61%

本书对C5重组单株抗体进行了简洁且权威的介绍，整合了科学证据、临床应用和商业性重点。

标靶补体C5的重组单株抗体领域正经历快速的技术改善和日益复杂的临床应用，因此，亟需为研发、临床和商业领域的领导者提供清晰实用的介绍。本文概述了靶向C5生物製剂的核心科学特征，将其作用机制置于补体通路调控的背景下进行阐述，并解释了为何选择性、效应功能调节和可生产性仍然是核心研发重点。

尖端工程技术、适应性临床设计与製造创新如何重塑C5疗法的开发路径与竞争优势

该产业正经历变革性的转变，重塑着C5标靶药物的发现、开发和定位方式。抗体工程技术的进步使得补体活性的精确调控成为可能，而Fc沉默设计和同型选择则降低了脱靶效应并提高了耐受性。同时，高解析度结构生物学和次世代定序技术的进步增强了表位定位和候选药物筛选，缩短了从先导化合物发现到候选药物优化的迭代週期。

对2025年美国对生物製药供应链和专案韧性征收关税的广泛营运和策略影响评估

近期贸易政策的调整生物製药（包括C5重组单株抗体）研发和商业化企业的营运成本会计引入了新的变数。关税措施及相关合规要求正在影响从全球供应链采购的原材料、一次性耗材和设备的投入成本，促使申办方和生产商重新评估筹资策略和库存管理政策。

详细的細項分析揭示了应用、产品类型、最终用户和研究领域的差异将如何从根本上改变开发重点和市场进入策略。

细分市场分析揭示了不同领域（临床、产品、终端用户和研究领域）的研发和商业化路径的差异。从应用角度来看，诊断领域强调伴随诊断和可靠的体外诊断测试对于识别有效患者群体的重要性，而研究性应用则侧重于临床研究以检验治疗假设，以及临床前研究以完善作用机制和安全性特征。这些基于应用领域的差异会影响证据预期、合作伙伴生态系统和转化里程碑时间表。

全面的区域观点：说明美洲、欧洲、中东和非洲以及亚太地区如何以独特的方式影响临床策略、监管计划和供应决策。

区域特征对产品开发、生产製造、监管规划和商业性合作等方面的策略选择有显着影响。美洲地区专注于先进的临床试验基础设施、支付方合作策略以及与诊断生态系统的整合，这为那些能够提供清晰的患者纳入伙伴关係并展现出良好安全性的项目创造了机会。该地区的临床和学术合作往往能够加速转化研究，并有助于快速检验生物标记主导的方法。

公司层面的策略趋势和伙伴关係模式定义了抗体设计、合约服务和诊断合作领域的竞争优势

成熟的生物製剂研发公司、专业抗体设计公司、合约服务供应商和诊断合作伙伴之间既竞争又合作的动态塑造了C5治疗生态系统。领先的生物製药公司正在投资新一代抗体形式和整合开发路径，将治疗项目与预测性生物标记和诊断策略联繫起来。专业设计公司提供差异化的平台，例如Fc修饰、半衰期延长和亲和性成熟，以加速先导药物最适化。

为领导者提供切实可行的策略指南，以协调抗体设计、诊断合作和稳健的供应策略，从而加速转化成功。

行业领导者应采取整合策略，将药物发现的优先事项与下游开发和商业化需求联繫起来。首先，应使抗体设计决策与明确的临床假设保持一致：选择与预期作用机制和安全性要求相匹配的同型和效应谱，并在正交的体外和体内模型中检验这些选择，以降低转化过程中的不确定性。其次，应在专案生命週期的早期阶段就纳入生物标记和诊断策略，以优化研究设计，并向监管机构和支付者提供清晰的价值提案。

采用严谨透明的混合研究途径，结合专家访谈、二手证据综合和情境分析，以获得切实可行的见解。

本研究采用多模态调查方法，结合专家访谈、文献综述和主题分析，以得出可靠的研究结果。主要资讯来源包括对药物发现、转化研究、监管事务和生产营运领域的专家进行结构化访谈，以了解实际应用中的限制因素和战术性策略。二级资讯来源，以阐明与C5抗体研发相关的技术进步、监管先例和临床设计创新。

整合关键的科学、监管和营运要求，这些要求共同决定了C5标靶生物製剂的转化成功。

总之，靶向补体C5的重组单株抗体的开发，是快速发展的科学、监管预期和实际操作三者相互交织的结果，这些因素共同决定了计画的可行性。儘管抗体设计和检测方法开发的进步为提高选择性和安全性提供了明确的途径，但成功的转化研究需要对生物标记、诊断和生产策略进行协调规划，以应对监管机构和支付方的审查。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按应用分類的补体C5重组单株抗体市场

  • 诊断
    • 伴随诊断
    • 用于体外诊断
  • 出于研究目的
    • 临床研究
    • 临床前研究
  • 治疗用途

9. 补体C5重组单株抗体市场（依产品类型划分）

  • IgG1
  • IgG2
  • IgG3
  • IgG4

第十章 依最终用户分類的补体C5重组单株抗体市场

  • 学术和研究机构
  • CRO（受託研究机构）
  • 诊断检查室
  • 製药和生物技术公司

第十一章 依研究领域分類的补体C5重组单株抗体市场

  • 自体免疫疾病
  • 感染疾病
  • 神经系统疾病
  • 肿瘤学

12. 各地区补体C5重组单株抗体市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 补体C5重组单株抗体市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国补体C5重组单株抗体市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国补体C5重组单株抗体市场

第十六章 中国补体C5重组单株抗体市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celltrion Inc.
  • Eli Lilly and Company
  • Horizon Therapeutics plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.
  • Sanofi
  • UCB SA
Product Code: MRR-4F7A6D4FB69A

The Complement C5 Recombinant Monoclonal Antibody Market was valued at USD 8.86 billion in 2025 and is projected to grow to USD 9.37 billion in 2026, with a CAGR of 7.61%, reaching USD 14.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.86 billion
Estimated Year [2026] USD 9.37 billion
Forecast Year [2032] USD 14.81 billion
CAGR (%) 7.61%

A concise and authoritative primer on C5 recombinant monoclonal antibodies that aligns scientific rationale with translational and commercial priorities

The landscape for complement C5 recombinant monoclonal antibodies is characterized by rapid technical refinement and increasingly sophisticated clinical applications, demanding a clear, actionable primer for leaders across research, clinical, and commercial functions. This introduction frames the core scientific attributes of C5-targeting biologics, situating their mechanism of action within complement pathway modulation and clarifying why selectivity, effector function tuning, and manufacturability remain central development priorities.

From an R&D perspective, rigorous target validation and assay standardization are essential to translate molecular efficacy into reproducible clinical signals. Concurrently, translational considerations such as biomarker selection, patient stratification strategies, and companion diagnostic alignment are becoming determinative factors in early-phase trial design. These scientific and operational vectors interact with regulatory expectations and payer dialogue, shaping program risks and go-to-market readiness.

This introduction also underscores the interdisciplinary coordination required to advance C5 therapeutics: discovery scientists, process engineers, clinical development teams, and commercial strategists must align on product profiles and evidence generation plans. By clarifying these foundational themes, stakeholders are better positioned to prioritize investments, refine hypotheses, and ensure that subsequent stages of development reflect both biological rationale and pragmatic development constraints.

How cutting-edge engineering, adaptive clinical design, and manufacturing innovations are reshaping development pathways and competitive advantage in C5 therapeutics

The sector is experiencing transformative shifts that reconfigure how C5-targeted agents are discovered, developed, and positioned. Advances in antibody engineering have enabled more precise modulation of complement activity, with Fc-silent formats and isotype selection reducing off-target effects and improving tolerability. At the same time, growth in high-resolution structural biology and next-generation sequencing has enhanced epitope mapping and candidate selection, shortening the iterative cycles between lead identification and candidate optimization.

Clinical trial design is also evolving; adaptive protocols and enriched enrollment based on molecular biomarkers are becoming standard approaches to demonstrate differentiated efficacy with smaller cohorts. Regulatory bodies increasingly expect robust mechanistic evidence and companion diagnostic strategies when benefit-risk profiles hinge on targeted patient populations. Commercially, partnerships between developers and diagnostic providers are more common, reflecting the necessity of aligning therapeutic claims with demonstrable patient selection strategies.

Finally, manufacturing and supply chain innovations are altering deployment timelines. Single-use bioreactors, intensified upstream processes, and improved analytic control strategies are enabling higher quality and consistency at scale. These technological, clinical, and operational inflections collectively create a more dynamic environment where speed, precision, and evidence alignment drive competitive advantage.

Evaluating the broad operational and strategic ramifications of recent United States tariff measures on biologics supply chains and program resilience in 2025

Recent trade policy adjustments have introduced new variables into the operational calculus for organizations that develop and commercialize biologics, including C5 recombinant monoclonal antibodies. Tariff measures and associated compliance requirements influence input costs for raw materials, single-use consumables, and equipment sourced across global supply chains, prompting sponsors and manufacturers to reassess sourcing strategies and inventory policies.

Beyond direct cost implications, tariffs exert indirect pressure by encouraging reconfiguration of manufacturing footprints and supplier relationships. Some organizations respond by onshoring critical stages of production or qualifying alternate vendors in tariff-neutral jurisdictions, while others pursue vertical integration to insulate key processes from cross-border trade volatility. These responses carry implications for capital deployment, timelines for capacity expansion, and regulatory submissions tied to specific manufacturing sites.

Importantly, tariff-related uncertainty also affects contracting and procurement behavior. Procurement teams increasingly build layered contingencies into supplier agreements and seek contractual terms that allocate tariff risk. Investors and partners evaluate program resilience to trade shocks as part of overall program de-risking, influencing strategic decisions around collaboration, licensing, and geographic rollout. In this context, a disciplined approach to supply chain visibility, tariff impact modeling, and scenario planning is essential to preserve program momentum and ensure consistent patient access.

In-depth segmentation insights revealing how application, product type, end-user, and research area distinctions fundamentally alter development priorities and go-to-market tactics

Segmentation analysis reveals how development and commercialization pathways diverge across distinct clinical, product, end-user, and research-area contexts. When considered through the lens of application, diagnostic settings emphasize the necessity of companion diagnostics and robust in vitro assays to identify responsive patient segments, while research use spans clinical research that validates therapeutic hypotheses and preclinical research that refines mechanism and safety profiles. These application-driven distinctions influence evidence expectations, partner ecosystems, and timelines for translational milestones.

Product-type segmentation likewise shapes technical strategy; IgG1 formats are often selected when effector function is desirable or tolerable, whereas IgG2, IgG3, and IgG4 subclasses are chosen to modulate effector interactions or to minimize complement activation, informing engineering decisions related to stability, half-life, and manufacturability. End-user segmentation further differentiates demand signals and support requirements: academic and research institutes prioritize novel tool antibodies and technical support for exploratory studies, contract research organizations focus on validated reagents and scalable protocols to serve client pipelines, diagnostic laboratories seek reproducible performance in regulated environments, and pharmaceutical and biotech companies demand GMP-aligned materials and regulatory documentation for translational progression.

Overlaying these axes is research-area segmentation, which directs therapeutic intent and safety considerations. Projects oriented to autoimmune disorders need durable modulation with careful immunogenicity management, infectious disease work prioritizes rapid neutralization and breadth against pathogen variants, neurological disorder programs must account for blood-brain barrier considerations and long-term tolerability, and oncology-focused efforts integrate complement modulation with immune-oncology strategies. Synthesizing these segmentation perspectives enables teams to prioritize candidate attributes, evidence generation plans, and partner selection aligned to the specific clinical and commercial contexts they target.

Comprehensive regional perspectives explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific uniquely influence clinical strategy, regulatory planning, and supply decisions

Regional dynamics materially influence strategic choices for product development, manufacturing, regulatory planning, and commercial engagement. In the Americas, emphasis on advanced clinical trial infrastructure, payer engagement strategies, and integration with diagnostic ecosystems creates opportunities for programs that can articulate clear patient selection criteria and demonstrate strong safety profiles. Clinical partnerships and academic collaborations in this region often accelerate translational studies and enable rapid validation of biomarker-driven approaches.

Europe, Middle East & Africa presents a heterogeneous regulatory and healthcare landscape where multi-jurisdictional submissions, regional reimbursement pathways, and variable access frameworks necessitate flexible market entry strategies. This region rewards precise evidence packages that account for local clinical practice patterns and health technology assessment requirements, and it encourages cross-border manufacturing strategies that mitigate tariff and logistic complexities.

Asia-Pacific is characterized by a combination of growing clinical research capacity, diverse regulatory environments, and rapidly expanding manufacturing competencies. Local regulatory pathways increasingly align with international standards while offering expedited review mechanisms for high-need therapies. Strategic collaborations with regional contract manufacturers, clinical centers of excellence, and diagnostic partners can reduce time to local proof-of-concept and support scalable supply operations. Taken together, these regional profiles inform prioritization of clinical sites, supply chain architecture, and stakeholder engagement plans to maximize development efficiency and patient access.

Strategic company-level dynamics and partnership models that define competitive advantage across antibody engineering, contract services, and diagnostic collaboration

Competitive and collaborative dynamics among established biologics developers, specialized antibody engineering firms, contract service providers, and diagnostic partners are shaping the C5 therapeutic ecosystem. Leading biopharmaceutical organizations are investing in next-generation antibody formats and integrated development pathways that couple therapeutic programs with predictive biomarkers and diagnostic strategies. Specialized engineering firms contribute differentiated platforms for Fc modification, half-life extension, and affinity maturation that accelerate lead optimization.

Contract research and manufacturing organizations play a pivotal role in enabling program scalability, offering modular process development, analytical method transfer, and GMP-compliant production that support both early clinical supply and later-stage manufacturing transitions. Diagnostic companies and pathology services are increasingly important collaborators for companion diagnostic co-development and for delivering the assays necessary to support enrollment criteria and post-market monitoring.

Partnership models vary from co-development agreements that align incentive structures around shared milestones to service-oriented engagements that provide discrete capabilities such as bioanalytical testing or cell-line development. Across these configurations, successful companies demonstrate discipline in evidence generation, transparent data packages for regulatory review, and clear commercialization pathways that anticipate payer and health system requirements. Ultimately, the ecosystem rewards organizations that couple scientific differentiation with operational excellence and strategic partnership execution.

Actionable strategic directives for leaders to harmonize antibody engineering, diagnostic alignment, and resilient supply strategies to accelerate translational success

Industry leaders should pursue integrated strategies that link discovery priorities with downstream development and commercialization imperatives. First, align antibody engineering decisions with a clear clinical hypothesis: select isotypes and effector profiles that match the intended mechanism and safety requirements, and validate these choices with orthogonal in vitro and in vivo models to reduce translational uncertainty. Second, embed biomarker and diagnostic planning early in the program lifecycle to enable enriched trial designs and clearer value propositions for regulators and payers.

Operationally, diversify supplier bases for critical raw materials and consider qualifying alternative manufacturing sites to reduce exposure to trade policy disruptions. Invest in analytics and digital tools that provide real-time visibility into procurement, lot traceability, and capacity constraints. From a partnership perspective, structure agreements with contract research and manufacturing organizations to allow rapid scale-up while preserving technical oversight and intellectual property safeguards.

Finally, drive stakeholder alignment through cross-functional governance that integrates scientific, regulatory, commercial, and supply chain perspectives. Use phased decision gates with defined data expectations to ensure resource allocation is commensurate with program risk and potential. By implementing these actions, organizations can increase resilience, shorten development timelines, and position programs to meet clinical and market expectations efficiently.

A rigorous and transparent mixed-methods research approach combining expert interviews, secondary evidence synthesis, and scenario-based analysis to derive practical insights

This research employed a multi-modal methodology combining primary expert engagement, secondary literature synthesis, and thematic analysis to produce robust insights. Primary inputs included structured interviews with subject-matter experts across discovery, translational research, regulatory affairs, and manufacturing operations to capture real-world constraints and tactical approaches. Secondary sources were systematically reviewed to contextualize technological advances, regulatory precedents, and clinical design innovations relevant to complement C5 antibody development.

Analytical techniques emphasized cross-validation of qualitative inputs, triangulating interview findings with documented case examples and peer-reviewed science to ensure conclusions reflect replicable phenomena rather than anecdotal observations. Regulatory and supply chain implications were examined through scenario mapping and sensitivity analysis to reveal common risk mitigations and strategic options. The methodology prioritized transparency of assumptions and traceability of evidence to support reproducible decision-making by stakeholders.

Ethical and compliance considerations were integrated throughout the process, ensuring that recommendations respect patient safety priorities, data integrity standards, and international regulatory norms. This methodological approach yields insights that are both actionable and defensible for teams preparing to advance C5-targeted therapeutics from discovery through clinical validation and commercial readiness.

Synthesis of critical scientific, regulatory, and operational imperatives that collectively determine the translational success of C5 targeted biologics

In closing, the development of complement C5 recombinant monoclonal antibodies intersects rapidly evolving science, regulatory expectations, and operational realities that together determine program viability. Technical progress in antibody engineering and assay development offers clear pathways to improved selectivity and safety profiles, yet successful translation requires coordinated planning around biomarkers, diagnostics, and manufacturing strategies that anticipate regulatory and payer scrutiny.

Stakeholders who invest in cross-functional alignment, robust supplier diversification, and early diagnostic co-development will be better positioned to navigate the complex decision points that characterize late preclinical and clinical stages. Additionally, proactive management of trade and supply risks, coupled with adaptive clinical designs, enhances resilience and preserves program momentum in the face of external shocks. The cumulative imperative is clear: disciplined evidence generation, operational adaptability, and strategic partnerships are the cornerstones of sustainable progress in this therapeutic space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Complement C5 Recombinant Monoclonal Antibody Market, by Application

  • 8.1. Diagnostic
    • 8.1.1. Companion Diagnostics
    • 8.1.2. In Vitro Diagnostics
  • 8.2. Research Use
    • 8.2.1. Clinical Research
    • 8.2.2. Preclinical Research
  • 8.3. Therapeutic

9. Complement C5 Recombinant Monoclonal Antibody Market, by Product Type

  • 9.1. IgG1
  • 9.2. IgG2
  • 9.3. IgG3
  • 9.4. IgG4

10. Complement C5 Recombinant Monoclonal Antibody Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Diagnostic Laboratories
  • 10.4. Pharmaceutical & Biotech Companies

11. Complement C5 Recombinant Monoclonal Antibody Market, by Research Area

  • 11.1. Autoimmune Disorders
  • 11.2. Infectious Diseases
  • 11.3. Neurological Disorders
  • 11.4. Oncology

12. Complement C5 Recombinant Monoclonal Antibody Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Complement C5 Recombinant Monoclonal Antibody Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Complement C5 Recombinant Monoclonal Antibody Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Complement C5 Recombinant Monoclonal Antibody Market

16. China Complement C5 Recombinant Monoclonal Antibody Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Biogen Inc.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Celltrion Inc.
  • 17.14. Eli Lilly and Company
  • 17.15. Horizon Therapeutics plc
  • 17.16. Janssen Pharmaceuticals, Inc.
  • 17.17. Merck & Co., Inc.
  • 17.18. Novartis AG
  • 17.19. Pfizer Inc.
  • 17.20. Regeneron Pharmaceuticals, Inc.
  • 17.21. Roche Holding AG
  • 17.22. Samsung Bioepis Co., Ltd.
  • 17.23. Sanofi
  • 17.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 130. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 133. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 151. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 154. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 158. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 161. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)